Goldman Sachs
CATX icon

Goldman Sachs’s Perspective Therapeutics CATX Stock Holding History

Goldman Sachs’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.91M Buy
1,733,078
+491,262
+40% +$1.86M ﹤0.01% 3734
2026
Q1 		$5.18M Buy
1,241,816
+1,081,979
+677% +$4.57M ﹤0.01% 3659
2025
Q4 		$440K Sell
159,837
-37,873
-19% -$108K ﹤0.01% 5671
2025
Q3 		$678K Sell
197,710
-74,388
-27% -$271K ﹤0.01% 5318
2025
Q2 		$936K Sell
272,098
-30,721
-10% -$81.1K ﹤0.01% 4762
2025
Q1 		$645K Sell
302,819
-600,099
-66% -$1.8M ﹤0.01% 5025
2024
Q4 		$2.88M Buy
902,918
+454,235
+101% +$3.71M ﹤0.01% 3983
2024
Q3 		$5.99M Buy
+448,683
New +$5.97M ﹤0.01% 3185
2024
Q2 		– Sell
-199,651
Closed -$2.38M – 5671
2024
Q1 		$2.38M Buy
+199,651
New +$1.7M ﹤0.01% 3748
2023
Q4 		– Sell
-1,337
Closed -$3.66K – 5640
2023
Q3 		$3.66K Buy
+1,337
New +$6.24K ﹤0.01% 5455
2016
Q1 		– Sell
-1,121
Closed -$11K – 7093
2015
Q4 		$11K Buy
+1,121
New +$14K ﹤0.01% 6956
2015
Q1 		– Sell
-1,101
Closed -$16K – 7091
2014
Q4 		$16K Sell
1,101
-6,557
-86% -$104K ﹤0.01% 7007
2014
Q3 		$129K Buy
7,658
+4,064
+113% +$101K ﹤0.01% 6452
2014
Q2 		$112K Buy
+3,594
New +$90.1K ﹤0.01% 6508

Other funds holding CATX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Goldman Sachs's CATX Position: Q2 2026 in Review

Goldman Sachs increased its Perspective Therapeutics (CATX) stake by 40% in Q2 2026, buying an estimated $1.86M and bringing the position to 1,733,078 shares worth $5.91M. The position accounts for ﹤0.01% of the portfolio, ranked #3734.

Goldman Sachs first reported a position in CATX in Q2 2014 and has held it in 14 quarters since. The position peaked at $5.99M in Q3 2024. 131 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

  • Goldman Sachs held 1,733,078 shares of Perspective Therapeutics worth $5.91M as of Q2 2026.
  • Goldman Sachs bought 491,262 Perspective Therapeutics shares in Q2 2026, an estimated $1.86M.
  • Perspective Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #3734 holding.
  • Goldman Sachs first reported a position in Perspective Therapeutics in Q2 2014 and has held it in 14 quarters since.
  • Goldman Sachs's Perspective Therapeutics position peaked at $5.99M in Q3 2024.
  • 131 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.